Short-Interval, Low-Dose [ 177 Lu]Lu-Prostate-Specific Membrane Antigen in the Treatment of Refractory Glioblastoma.

Authors :: More S
Naiker T
Jacobs N
Oompie F
Prasad V
Source :: Clinical nuclear medicine [Clin Nucl Med] 2023 May 01; Vol. 48 (5), pp. e217-e218. Date of Electronic Publication: 2023 Mar 05.
Publication Year :: 2023
Abstract: Abstract: Prostate-specific membrane antigen (PSMA) is expressed on the neovasculature as well as to some extent on the glioblastoma cells. With this background, we report the case of a 34-year-old man with recurrent glioblastoma who was treated with 2 cycles of low-dose [ 177 Lu]Lu-PSMA after exhausting all available treatment options in the state sector. Baseline imaging demonstrated intense PSMA signal in the known lesion, which was amenable to therapy. The prospect of [ 177 Lu]Lu-PSMA-based therapy for glioblastoma is warranted going forward.<br />Competing Interests: Conflicts of interest and sources of funding: none declared.<br /> (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)

Subjects :: Male
Humans
Adult
Radiopharmaceuticals therapeutic use
Prostate pathology
Prostate-Specific Antigen
Neoplasm Recurrence, Local drug therapy
Lutetium therapeutic use
Heterocyclic Compounds, 1-Ring therapeutic use
Dipeptides therapeutic use
Treatment Outcome
Glioblastoma diagnostic imaging
Glioblastoma radiotherapy
Glioblastoma drug therapy
Prostatic Neoplasms, Castration-Resistant pathology

Full Text Access

Tools